Heterologous prime-boost cellular vaccination induces potent antitumor immunity against triple negative breast cancer

Treatment landscape of triple-negative breast cancer — expanded options, evolving needs

(2021) Giampaolo Bianchini et al.   Nature Reviews Clinical Oncology

Oncolytic vesicular stomatitis virus–based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8+T-cell functionality

(2020) Seyedeh-Raheleh Niavarani et al.   Journal for ImmunoTherapy of Cancer

Oncolytic Viruses and the Immune System: The Dynamic Duo

(2020) Ana Lemos de Matos et al.   Molecular Therapy-Methods & Clinical Development

Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy

(2019) Pamela C. Rosato et al.   Nature Communications

Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers

(2019) Tina Gruosso et al.   JOURNAL OF CLINICAL INVESTIGATION

Recent advances in triple negative breast cancer: the immunotherapy era

(2019) Antonio Marra et al.   BMC Medicine

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Peter Schmid et al.   LANCET ONCOLOGY

Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer

(2019) Jenna H. Newman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy

(2018) Marie-Claude Bourgeois-Daigneault et al.   Science Translational Medicine

Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy

(2018) Carole Achard et al.   EBioMedicine

T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection

(2018) Jonathan A. Trujillo et al.   Cancer Immunology Research

Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity

(2018) Orneala Bakos et al.   Journal for ImmunoTherapy of Cancer

Cancer immunoediting and resistance to T cell-based immunotherapy

(2018) Jake S. O’Donnell et al.   Nature Reviews Clinical Oncology

NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

(2017) Almohanad A. Alkayyal et al.   Cancer Immunology Research

Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer

(2017) Thomas Karn et al.   JAMA Oncology

Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer

(2016) Jonathan Oh et al.   GYNECOLOGIC ONCOLOGY

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

(2016) Brian D. Lehmann et al.   PLoS One

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

(2015) Abhishek D. Garg et al.   Frontiers in Immunology

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

(2014) S. Loi et al.   ANNALS OF ONCOLOGY

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

(2014) Sylvia Adams et al.   JOURNAL OF CLINICAL ONCOLOGY

Summary of bi-shRNAfurin/GM-CSF Augmented Autologous Tumor Cell Immunotherapy (FANG™) in Advanced Cancer of the Liver

(2014) John Nemunaitis et al.   ONCOLOGY

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

(2014) Lee-Hwa Tai et al.   Jove-Journal of Visualized Experiments

Measles Virus Vaccine-Infected Tumor Cells Induce Tumor Antigen Cross-Presentation by Human Plasmacytoid Dendritic Cells

(2013) J.-B. Guillerme et al.   CLINICAL CANCER RESEARCH

Preventing Postoperative Metastatic Disease by Inhibiting Surgery-Induced Dysfunction in Natural Killer Cells

(2012) L.-H. Tai et al.   CANCER RESEARCH

Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma

(2012) G. Erdag et al.   CANCER RESEARCH

Harnessing Oncolytic Virus-mediated Antitumor Immunity in an Infected Cell Vaccine

(2012) Chantal G Lemay et al.   MOLECULAR THERAPY

Sequence analysis of mutations and translocations across breast cancer subtypes

(2012) Shantanu Banerji et al.   NATURE

Whole Cell Vaccines—Past Progress and Future Strategies

(2012) Bridget P. Keenan et al.   SEMINARS IN ONCOLOGY

Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer

(2012) Michael G. Hanna et al.   Human Vaccines & Immunotherapeutics

Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer

(2011) Neil Senzer et al.   MOLECULAR THERAPY

Reciprocal Human Dendritic Cell-Natural Killer Cell Interactions Induce Antitumor Activity Following Tumor Cell Infection by Oncolytic Reovirus

(2009) R. J. Prestwich et al.   JOURNAL OF IMMUNOLOGY